Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 19, 2017
Pharmacy Choice - Pharmaceutical News - Innovus Pharma Files Its Product License Application in Canada for the Commercialization of Vesele as a Natural Health Product to Help Improve Symptoms of Sexual Dysfunction - November 19, 2017

Pharmacy News Article

 5/18/17 - Innovus Pharma Files Its Product License Application in Canada for the Commercialization of Vesele as a Natural Health Product to Help Improve Symptoms of Sexual Dysfunction

SAN DIEGO(BUSINESS WIRE) Innovus Pharmaceuticals, Inc. (the Company or Innovus Pharma) (OTCQB Venture Market: INNV) today announced that the Company filed its Product License Application with Health Canada as a Natural Health Product (NPN) to market its current best-selling product Vesele with the indication to Help Improve Symptoms of Sexual Dysfunction. If accepted by Health Canada, Vesele will be available over-the-counter (OTC) in 120 capsule bottles and will not require a prescription. The product if approved will not be reimbursed by the Canadian government, therefore, the Company will be able to set the retail price as it does in the United States. If approved, the Company expects to directly launch the product itself through its Beyond Human sales and marketing platform currently being set up in Canada and through other sales channels.

Based on Health Canada's approval process, the approval process normally takes up to six (6) months in Canada for this type of product, assuming no additional information is requested by Health Canada.

If approved by Health Canada for commercialization in Canada, Vesele will be our fourth product on the Canadian market including Zestra, Zestra Glide and EjectDelay sold under the name Uxor? by our partner Orimed Pharma, said Dr.Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. Having Vesele be an NPN in Canada, bearing the indication of 'Help Improve Symptoms of Sexual Dysfunction,' would be a great value add to the product and a great accomplishment for the Company, continued Dr. Damaj.

Vesele is a proprietary oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine. Vesele was formulated to increase blood flow and nitric oxide production.

As previously reported, a U.S. human clinical use survey was completed on Vesele to evaluate erectile dysfunction and sexual satisfaction in men using Vesele twice daily for up to four months with the following favorable results:

1. 49.5% increase in erection hardness
2. 44.5% increase in erection maintenance
3. 34.6% increase in desire for sexual activity
4. 34.1% increase the ability to satisfy the partner

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists,gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (ANDA) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to;;;;;;;;;;; and

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully receive approval for Vesele in Canada and commercialize this product therein, and commercialize other products in the U.S. and internationally and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Emerging Markets Consulting, LLC

James S. Painter III


Source: Innovus Pharmaceuticals, Inc.

Copyright Business Wire 2017

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement